58584-92-2

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
2-Amino-5-chloropyridine-3-carboxylic acid is utilized as a key intermediate in the synthesis of various pharmaceuticals and agrochemicals. Its capacity to form strong bonds with biological molecules allows for the development of new drugs and pesticides with enhanced efficacy and selectivity.
Used in Drug Discovery and Development:
As a valuable tool in drug discovery and development, 2-Amino-5-chloropyridine-3-carboxylic acid aids in the design and optimization of novel therapeutic agents. Its interaction with proteins and enzymes facilitates the identification of potential drug targets and the evaluation of compound potency and selectivity.
Used as a Corrosion Inhibitor in Industrial Applications:
2-Amino-5-chloropyridine-3-carboxylic acid has demonstrated potential as a corrosion inhibitor in various industrial settings. Its ability to form strong bonds with metal surfaces can help prevent corrosion and extend the service life of equipment and structures, contributing to improved safety and cost-effectiveness in industrial operations.

Upstream product

• 38496-18-3 2,6-dichloropyridine-3-carboxylic acid 
• 849805-25-0 methyl 2-amino-6-chloropyridine-3-carboxylate 
• 64-17-5 ethanol 
• 52471-07-5 2-amino-6-chloro-3-cyanopyridine 
• 60-35-5 acetamide 

Downstream Products

• 849805-55-6 2-amino-N-(4-(benzyloxy)benzyl)-6-chloronicotinamide 
• 849805-25-0 methyl 2-amino-6-chloropyridine-3-carboxylate 
• 64321-24-0 2-amino-6-chloro-pyridine-3-carboxamide 
• 1005490-20-9 C₁₂H₉ClFN₃O 
• 1196156-84-9 2-amino-6-methoxynicotinic acid 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS AS MTOR INHIBITORS

The present disclosure describes novel heterocyclic mTOR inhibitors and methods for preparing them. The pharmaceutical compositions comprising such mTOR inhibitors and methods of using them for treating cancer, infectious diseases, and other mTOR associated disorders are also described.

PYRIDOPYRIMIDINE COMPOUNDS ACTING AS MTORC 1/2 DOUBLE-KINASE INHIBITORS

Disclosed are a series of pyridopyrimidine compounds and a use of same in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors, and specifically disclosed is a use of the compounds as shown in formula (IV), tautomers thereof or pharmaceutically acceptable salts thereof in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors.

HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS

The present invention provides heterocyclic compounds, the stereoisomer thereof, the enantiomer thereof, or the pharmaceutically acceptable salt, which are capable of modulating the activity of Mer receptor tyrosine kinase (MERTK). This invention also provides pharmaceutical compositions thereof, methods to prepare the said compounds, and the use of such compounds as a medicament. The present invention is directed to MERTK inhibitory compounds with marked potency, thereby having an outstanding potential for a pharmaceutical intervention of cancer and any other diseases related to MERTK dysregulation.

BENZOXAZINONE DERIVATIVES AND ANALOGUES THEREOF AS MODULATORS OF TNF ACTIVITY

A series of substituted 3,4-dihydro-2H-.1,4-benzoxazin-3-one derivatives, and analogues thereof, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune

Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014

The optimization of a potent and highly selective series of dual mTORC1 and mTORC2 inhibitors is described. An initial focus on improving cellular potency whilst maintaining or improving other key parameters, such as aqueous solubility and margins over hERG IC50, led to the discovery of the clinical candidate AZD8055 (14). Further optimization, particularly aimed at reducing the rate of metabolism in human hepatocyte incubations, resulted in the discovery of the clinical candidate AZD2014 (21).

Synthesis and properties of 5-cyano-substituted nucleoside analog with a donor-donor-acceptor hydrogen-bonding pattern

6-Aminopyridin-2-ones form Watson-Crick pairs with complementary purine analogues to add a third nucleobase pair to DNA and RNA, if an electron-withdrawing group at position 5 slows oxidation and epimerization. In previous work with a nucleoside analogue trivially named dZ, the electron withdrawing unit was a nitro group. Here, we describe an analogue of dZ (cyano-dZ) having a cyano group instead of a nitro group, including its synthesis, pKa, rates of acid-catalyzed epimerization, and enzymatic incorporation.

NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF

The disclosure relates to compounds of formula (I): wherein A, Z, Z′, L, R2 and R3 are as defined in the disclosure, to compositions comprising said compounds, and to methods for the manufacture and therapeutic use thereof.

HETEROCYCLIC JAK KINASE INHIBITORS

The present invention relates to compounds of Formula (I) and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds provide a treatment for myeloproliferative disorders and cancer

COMPOSITION FOR AGRICULTURAL USE FOR CONTROLLING OR PREVENTING PLANT DISEASES CAUSED BY PLANT PATHOGENS

Disclosed is a composition for agricultural use, which is used for controlling or preventing plant diseases caused by plant pathogens. The composition for agricultural use contains a compound represented by formula (1), a salt thereof or a hydrate of the compound or the salt. (1) [In the formula, Z represents an oxygen atom, a sulfur atom or NRz; and E represents a furyl group, a thienyl group, a pyrrolyl group, a tetrazolyl group, a thiazolyl group, a pyrazolyl group, a phenyl group or the like.]

COMBINATION 059

This invention relates to a combination product, as defined herein, comprising a MEK inhibitor and a mTOR-selective inhibitor, and to methods for the production of an anti-cancer effect in a patient, which is accordingly useful in the treatment of cancer in a patient. More specifically the present invention relates to; a combination product, as defined herein, comprising a MEK inhibitor and a mTOR-selective inhibitor; a combination product, as defined herein, comprising a kit of parts comprising a MEK inhibitor and a mTOR-selective inhibitor; use of the combination product, as defined herein, in the treatment of cancer; a method of treating cancer comprising administering the combination product, as defined herein, to a patient. The combination product, as defined herein, and methods of the invention are also useful in the treatment of other diseases associated with the activity of MEK, and/or mTOR.